Balyasny Asset Management’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-300,103
Closed -$6.27M 2580
2021
Q1
$6.27M Sell
300,103
-102,224
-25% -$2.36M 0.03% 616
2020
Q4
$9.21M Buy
402,327
+19,683
+5% +$375K 0.05% 453
2020
Q3
$6.24M Buy
382,644
+142,847
+60% +$2.59M 0.05% 528
2020
Q2
$3.25M Sell
239,797
-40,578
-14% -$472K 0.03% 616
2020
Q1
$3.32M Buy
280,375
+105,989
+61% +$2.35M 0.04% 500
2019
Q4
$4.34M Buy
174,386
+152,025
+680% +$3.08M 0.03% 620
2019
Q3
$380K Buy
+22,361
New +$407K ﹤0.01% 991
2019
Q2
Sell
-146,267
Closed -$4.7M 1813
2019
Q1
$4.7M Buy
146,267
+137,280
+1,528% +$4.25M 0.03% 579
2018
Q4
$253K Buy
+8,987
New +$263K ﹤0.01% 1265
2018
Q2
Sell
-182,158
Closed -$7.16M 2270
2018
Q1
$7.16M Buy
+182,158
New +$6.65M 0.03% 609
2017
Q3
Sell
-29,945
Closed -$837K 2162
2017
Q2
$837K Buy
+29,945
New +$678K ﹤0.01% 1151
2016
Q2
Sell
-11,580
Closed -$220K 1534
2016
Q1
$220K Buy
+11,580
New +$210K ﹤0.01% 1097
2015
Q4
Sell
-26,450
Closed -$619K 1523
2015
Q3
$619K Buy
+26,450
New +$730K ﹤0.01% 788

Other funds holding XENT

Balyasny Asset Management's XENT Position: Q2 2021 in Review

Balyasny Asset Management sold out of Intersect ENT, Inc (XENT) in Q2 2021, closing a stake of 300,103 shares — an estimated $6.27M sold.

Balyasny Asset Management first reported a position in XENT in Q3 2015 and held it in 13 quarters. The position peaked at $9.21M in Q4 2020. 107 funds tracked by Wall St. Rank hold XENT as of Q2 2021.

  • Balyasny Asset Management reported no remaining Intersect ENT, Inc position as of Q2 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 300,103 Intersect ENT, Inc shares in Q2 2021, an estimated $6.27M.
  • Balyasny Asset Management first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 13 quarters.
  • Balyasny Asset Management's Intersect ENT, Inc position peaked at $9.21M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.